These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 2683263

  • 1. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients.
    Michael HJ, Francos GC, Burke JF, Besarab A, Moritz M, Gillum D, Jarrell B.
    Transplantation; 1989 Nov; 48(5):805-8. PubMed ID: 2683263
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine.
    Canafax DM, Torres A, Fryd DS, Heil JE, Strand MH, Ascher NL, Payne WD, Sutherland DE, Simmons RL, Najarian JS.
    Transplantation; 1986 Feb; 41(2):177-81. PubMed ID: 3511581
    [Abstract] [Full Text] [Related]

  • 5. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE, Fryd DS, Strand MH, Canafax DM, Ascher NL, Payne WD, Simmons RL, Najarian JS.
    Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
    Johnson CP, Simmons RL, Sutherland DE, Canafax DM, Ascher NL, Payne WD, Flick B, Najarian JS, Fryd DS.
    Transplantation; 1988 Feb; 45(2):380-5. PubMed ID: 3278431
    [Abstract] [Full Text] [Related]

  • 7. Sequential antilymphoblast globulin and cyclosporine for renal transplantation.
    Sommer BG, Henry M, Ferguson RM.
    Transplantation; 1987 Jan; 43(1):85-90. PubMed ID: 3541330
    [Abstract] [Full Text] [Related]

  • 8. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation.
    Griño JM, Alsina J, Sabater R, Castelao AM, Gil-Vernet S, Andres E, Sabate I, Mestre M, Seron D, Diaz C.
    Transplantation; 1990 Jun; 49(6):1114-7. PubMed ID: 2360253
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of cyclosporine and delayed graft function on posttransplantation erythropoiesis.
    Besarab A, Caro J, Jarrell B, Burke J, Francos G, Mallon E, Karsch R.
    Transplantation; 1985 Dec; 40(6):624-31. PubMed ID: 3907033
    [Abstract] [Full Text] [Related]

  • 11. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Mestre M, Torras J, Alsina J.
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [Abstract] [Full Text] [Related]

  • 12. Timing of cyclosporine administration in patients with delayed graft function.
    Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ.
    J Surg Res; 1987 Dec; 43(6):489-94. PubMed ID: 3320528
    [Abstract] [Full Text] [Related]

  • 13. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine.
    Halloran PF, Aprile MA, Farewell V, Ludwin D, Smith EK, Tsai SY, Bear RA, Cole EH, Fenton SS, Cattran DC.
    Transplantation; 1988 Aug; 46(2):223-8. PubMed ID: 3043779
    [Abstract] [Full Text] [Related]

  • 14. The long-term effect of delayed graft function on cadaveric renal transplants treated with low-dose cyclosporine.
    Miwa H, Van Loenen M, Vanderwerf BA.
    Clin Transpl; 1989 Aug; ():275-80. PubMed ID: 2487572
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [Abstract] [Full Text] [Related]

  • 18. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B.
    Transplantation; 2008 Dec 27; 86(12):1732-7. PubMed ID: 19104413
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A, Moreso FJ, Seron D, Gil-Vernet S, Cruzado JM, Castelao AM, Grinyó JM.
    Transplant Proc; 2004 Jun 27; 36(5):1305-7. PubMed ID: 15251318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.